NAUT - Nautilus Biotechnology, Inc.
IEX Last Trade
1.72
-1.155 -67.151%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:21:35 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
19.80%
PREVIOUS CLOSE
CHG
CHG%
$2.88
-1.16
-40.17%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-1.70%
1 Month
-29.10%
3 Months
-38.65%
6 Months
-23.11%
1 Year
-47.73%
2 Year
-6.49%
Key data
Stock price
$1.72
DAY RANGE
$1.74 - $2.88
52 WEEK RANGE
$1.76 - $3.45
52 WEEK CHANGE
-$48.97
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/29/2024
Company detail
CEO: Sujal M. Patel
Region: US
Website: nautilus.bio
Employees: 130
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: nautilus.bio
Employees: 130
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company was founded in 2016 and is headquartered in Seattle, Washington.
Recent news